|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for 101928916 |
 Gene summary |
| Basic gene Info. | Gene symbol | 101928916 |
| Gene name | ||
| Synonyms | ||
| Cytomap | UCSC genome browser: | |
| Type of gene | ||
| RefGenes | ||
| Description | ||
| Modification date | ||
| dbXrefs | ||
| Protein | UniProt: P40261 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_101928916 | |
| BioGPS: 101928916 | ||
| Pathway | NCI Pathway Interaction Database: 101928916 | |
| KEGG: 101928916 | ||
| REACTOME: 101928916 | ||
| Pathway Commons: 101928916 | ||
| Context | iHOP: 101928916 | |
| ligand binding site mutation search in PubMed: 101928916 | ||
| UCL Cancer Institute: 101928916 | ||
| Assigned class in mutLBSgeneDB | ||
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for 101928916 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for 101928916 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | C141 | L139P | -1.5806034 | G63 | D61N | -1.4089758 | Y204 | M205T | -1.2358818 | G63 | G63D | -1.1606107 | D85 | D85G | -1.1373302 | Y25 | K26R | -0.86499042 | Y20 | D19N | -0.81602399 | Y11 | Y11C | -0.77959695 | A198 | A198V | -0.76086613 | N90 | L91Q | -0.71771003 | Y204 | I206L | -0.16487276 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for 101928916 from PDB |
| Top |
| Differential gene expression and gene-gene network for 101928916 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for 101928916 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for 101928916 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved|investigational|nutraceutical | DB00627 | Niacin | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of 101928916 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | SAH | S-ADENOSYL-L-HOMOCYSTEINE | 3rod | C | Y11 Y20 Y25 G63 D85 C141 | SAH | S-ADENOSYL-L-HOMOCYSTEINE | 2iip | A | Y11 Y20 Y25 G63 D85 N90 C141 | SAH | S-ADENOSYL-L-HOMOCYSTEINE | 2iip | B | Y11 Y20 Y25 G63 D85 N90 C141 | SAH | S-ADENOSYL-L-HOMOCYSTEINE | 2iip | C | Y11 Y20 Y25 G63 D85 N90 C141 | SAH | S-ADENOSYL-L-HOMOCYSTEINE | 2iip | D | Y11 Y20 Y25 G63 D85 N90 C141 | SAH | S-ADENOSYL-L-HOMOCYSTEINE | 3rod | A | Y11 Y20 Y25 G63 D85 N90 C141 | SAH | S-ADENOSYL-L-HOMOCYSTEINE | 3rod | B | Y11 Y20 Y25 G63 D85 N90 C141 | SAH | S-ADENOSYL-L-HOMOCYSTEINE | 3rod | D | Y11 Y20 Y25 G63 D85 N90 C141 | NCA | NICOTINAMIDE | 3rod | A | Y20 A198 Y204 | NCA | NICOTINAMIDE | 3rod | B | Y20 Y204 | NCA | NICOTINAMIDE | 3rod | C | Y20 Y204 | NCA | NICOTINAMIDE | 3rod | D | Y20 Y204 |
| Top |
| Conservation information for LBS of 101928916 |
| Multiple alignments for P40261 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |